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Introduction
High-grade osteosarcoma is the most common bone
malignancy in children. Its incidence in this popula-
tion varies significantly with age, with peak incidence
occurring in the second decade of life during the ado-
lescent growth spurt, a feature that suggests a relation-
ship between rapid bone growth and the development
of malignancy.
In children younger than 10 years, Ewing’s sarcoma
is more common than osteosarcoma,1 and preadoles-
cents amount to only a small proportion of patients
with osteosarcoma. Because their physical status is
distinct from that of adolescents, the pathophysiology
of osteosarcoma development in this group might be
different from that in adolescents. Thus far, reports
on the clinical features among preadolescent patients
have shown conflicting results; some reports suggest
a poorer prognosis for preadolescent patients,2–4
whereas others show no difference.5–8 There are no
reports of osteosarcoma in preadolescent patients in
Taiwan. In this study, we observed 13 preadolescents
with high-grade osteosarcoma treated at our hospital
and compared the findings with those seen in 58 ado-
lescent patients to assess the differences in prognosis
and clinical appearance of the malignancy.
Methods
Patients
Between January 1980 and January 2006, 75 patients
younger than 18 years received treatment for high-
grade osteosarcoma at the Department of Pediatrics,
Taipei Veterans General Hospital. Four adolescent
patients were excluded because of incomplete medical
records. Among the remaining 71 patients, 13 were
preadolescents, defined as children younger than 10
years of age. Their clinical course was observed and
the following data were collected: age, sex, primary
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metastasis or pathologic fracture, tumor location, alka-
line phosphatase (ALP) level before treatment, type
of surgery, tumor necrosis induced by chemotherapy,
and survival outcome. High ALP level, which differs
with age, was defined according to the Lockitch et al9
report. Tumor necrosis rate was assessed by the patho-
logic reports, and good responders were defined as
those with a necrosis rate ≥ 90% and poor responders
as those with a necrosis rate < 90%.
Diagnosis and follow-up
Osteosarcoma was diagnosed on the basis of tumor
biopsy reports. For staging, all patients underwent chest
X-rays, chest computed tomography (CT), and whole-
body bone scanning. Primary lesion detection was car-
ried out with X-ray and magnetic resonance imaging
(MRI). All the examinations were repeated before de-
finitive surgery. After surgery, chest and primary lesion
X-rays, chest CT, and whole-body bone scanning were
performed every 3 months throughout the period of
adjuvant chemotherapy. After completion of the entire
treatment course, all patients were followed every 
3 months during the first 2 years, every 6 months for
the following 3 years and then yearly thereafter.
Chemotherapy
Over the long study period (Table 1), the chemother-
apy protocol changed but still included neoadjuvant
and adjuvant chemotherapy. The preadolescent and
adolescent patients were treated with the same proto-
col. Before May 2003, the chemotherapy protocol was
unstratified, consisting of high-dose methotrexate,
epirubicin, cisplatin and ifosfamide, with surgery per-
formed at week 15. For intensification of chemother-
apy, a new protocol, similar to the regimens from the
Rizzoli Institute,10 was adopted after May 2003. The
new protocol increased the accumulative doses of cis-
platin and ifosfamide, with decreased frequency of
methotrexate usage, and substituted epirubicin with
doxorubicin.
Postoperative adjuvant chemotherapy was stratified
according to the tumor necrosis rate to avoid exces-
sive chemotherapy in good responders. Good respon-
ders and poor responders received 2 and 3 cycles of the
4 drugs (high-dose methotrexate, doxorubicin, cis-
platin, and ifosfamide), respectively. In patients with
primary metastasis or relapse, the same chemothera-
peutic agents with a higher accumulative dose or other
salvage chemotherapeutics were administered depend-
ing on the primary doctors’ decision.
Surgery
Most patients underwent limb-salvage surgery instead
of amputation when possible. The type of surgery
depended on the location and extension of the tumor,
neurovascular involvement, and the presence of com-
plicating factors such as pathologic fracture. The type
of reconstruction after tumor resection included the
use of prosthesis, extracorporeally irradiated autograft-
prosthetic composite arthroplasty,11 reconstruction
with autograft or allograft,12 and allograft arthrodesis,13
as previously reported.
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Table 1. Patient characteristics and operation results of the 13 Taiwanese preadolescent patients with high-grade osteosarcoma
Patient # (yr of Traditional 
diagnosis)/ Age (yr)/
Primary site ALP (U/L) Histology
therapy/ Type of Necrosis rate 
primary sex duration of surgery (Grade)†
metastasis symptoms
1 (1995) 8.7/M Femur, D 418 Osteoblastic NR/2 mo Limb-salvage NA
2 (1996) 9.5/M Tibia, P 395 Osteoblastic Yes/2 mo Amputation NA
3 (1997) 6.9/F Femur, D 349 Osteoblastic* NR/1 mo Limb-salvage NA
4 (1997) 7.0/F Femur, D 212 Osteoblastic NR/1 mo Limb-salvage II
5 (1999)/lung 8.3/F Femur, D 228 Osteoblastic Yes/1 mo Limb-salvage II
6 (2000) 6.4/M Femur, D 583 (h) Osteoblastic Yes/2 mo Amputation II
7 (2001) 5.7/M Femur, P 1,353 (h) Osteoblastic Yes/0.5 mo Limb-salvage I
8 (2002)/bone 8.8/F Femur, D 302 Osteoblastic* Yes/1 mo Limb-salvage IV
9 (2002) 5.5/M Humerus, P 252 Telangiectatic Yes/2.5 mo Limb-salvage II
10 (2003) 4.8/F Tibia, P 470 (h) Osteoblastic Yes/1 mo Limb-salvage II
11 (2003) 9.2/M Femur, D 1,619 (h) Osteoblastic Yes/2.5 mo Limb-salvage II
12 (2004) 8.7/M Tibia, P 402 Osteoblastic No/1 mo Limb-salvage III
13 (2005) 6.7/M Tibia, P 195 Osteoblastic NR/0.5 mo Amputation II
*With pathologic fracture; †necrosis rate induced by neoadjuvant chemotherapy (Grades I, II, III and IV indicate < 10%, 10–90%, > 90% and 100%, respectively).
D = distal; P = proximal; h = high; NR = not reported.
Statistical analysis
Overall survival was defined as the time from diagnosis
of the tumor until death or last patient contact,
whichever occurred first. The overall survival rates were
measured using the Kaplan-Meier method and com-
pared using the log-rank test between the groups. The
differences between preadolescent and adolescent
patients were examined using the χ2 test or Fisher’s
exact test. A p value < 0.05 was considered to be statis-
tically significant.
Results
Findings in the preadolescent patients
The preadolescent group comprised 8 males and 
5 females. Their clinical features, treatment protocol,
and outcome are summarized in Tables 1 and 2.14,15
The median age was 7.0 years (range, 4.8–9.5 years).
The osteoblastic type was the most common histo-
logic type (12 patients), and the distal femur was the
most common primary tumor location (7 patients).
Two patients had pathologic fractures at diagnosis
(patients 3 and 8), and 2 were considered to have pri-
mary metastasis (patients 5 and 8). The median ALP
level at diagnosis was 395 U/L (range, 195–1,619 U/
L). In 11 patients without primary metastasis, the
median ALP level was 402U/L (range, 195–1,619U/
L; Table 1). Four preadolescent patients had high ALP
levels according to age-adjusted normal ranges.
All the 13 patients received chemotherapy and sur-
gery; 12 received the entire treatment, of which 10 were
treated with the pre-2003 protocol, and 2 received the
new protocol. One patient (patient 4) received another
J Chin Med Assoc • September 2009 • Vol 72 • No 9 457
Osteosarcoma in preadolescent patients
Table 2. Treatment and outcome of the 13 Taiwanese preadolescent patients with high-grade osteosarcoma
Patient # (yr of Primary chemotherapy and reasons Months to 
Treatment at relapse
Survival (mo)/
diagnosis) for protocol violation relapse (site) outcome
1 (1995) MCIE; early surgery due to tumor 41 (lung) Wedge resection of lung, 53/D
progression C/T, R/T over brain and lung,
PBSCT (Reference 14)
2 (1996) MCIE; amputation initially due to – – 134/NED
large tumor
3 (1997) MCIE – – 125/NED
4 (1997) MCIE, VP16 13 (local) Amputation, C/T, PBSCT 31/D
5 (1999) MCIE; suspended C/T prematurely 29 (lung) Tumor excision and 30/D
due to renal insufficiency and pneumolysis, C/T
severe electrolyte imbalance
6 (2000) MCIE; amputation initially because of – – 86/NED
encasement of neurovascular bundle
7 (2001) MCIE 20 (L3 and R/T, resection, C/T 78/free of 
retroperitoneum) (cyclophosphamide, VP16, disease
carboplatin)
8 (2002) MCIE 15 (humerus) Resection, R/T, C/T 33.5/D
(carboplatin,
cyclophosphamide, MTX,
ifosfamide, topotecan)
9 (2002) MCIE; previously C/T 3 times at another – – 60/NED
hospital, substituted epirubicin for 
lipodox due to chest pain
10 (2003) MCIA, VP16; changed C/T after surgery 10 (lung) Multiple thoracotomies, C/T 31/D
due to poor tumor necrosis rate
11 (2003) MCIEA; previously C/T once at another 20 (ankle) C/T (MCIE, VP16), R/T 32.5/D
hospital
12 (2004) MCIA; ifosfamide induced acute – – 37/NED
pancreatitis twice, reduced 
ifosfamide dosage (Reference 15)
13 (2005) MCIA; refused C/T initially, tumor – – 34/NED
progressed, amputation 1 mo later
MCIEA = methotrexate, cisplatin, ifosfamide, epirubicin, adriamycin; VP16 = etoposide; C/T = chemotherapy; R/T = radiotherapy; PBSCT = autologous peripheral
blood stem cell transplant; D = died of disease; NED = no evidence of disease.
chemotherapy regimen (TPOG-OS94 protocol)16
before she was referred to our hospital for surgery after
local recurrence. Patient 10 was the only one unable
to complete the scheduled chemotherapy because of
pulmonary metastases during adjuvant chemotherapy,
and alternative chemotherapy was adopted subsequently.
Three patients underwent amputation because of
large tumor size, involvement of neurovascular bun-
dles, and aggressive tumor progression despite coad-
ministration of chemotherapy. The other 10 patients
underwent limb-salvage surgery; 5 received arthrodesis
and 1 (patient 3) underwent a lengthening operation
for leg discrepancy after skeletal maturity. The tumor
necrosis rate induced by neoadjuvant chemotherapy
was evaluated in 10 patients, with only 2 showing a
good histologic response.
Two of the 13 patients had primary metastasis
(Table 1, patients 5 and 8). Patient 5 had a solitary
subpleural nodule that disappeared temporarily on the
chest CT after chemotherapy. However, 18 months
after completing the entire chemotherapy regimen,
lung metastasis occurred and was pathologically proven
by wedge resection. Patient 8 had bone metastasis over
the left proximal humerus, which was initially revealed
by a bone scan. It was not determined by the first
biopsy during the limb-salvage surgery and was dis-
covered 11 months later when a painful swelling devel-
oped and rebiopsy was performed. Of the remaining
11 patients, 5 relapsed; 2 had lung metastases, 1 had
local recurrence, and 2 developed bone metastases
(Table 2). The therapy regimens for the 7 patients with
metastasis or relapse are shown in Table 2.
All the 7 patients received chemotherapy, 6 under-
went surgery for tumor removal, 4 received palliative
radiation for local control, and 2 received high-dose
chemotherapy with an autologous peripheral blood
stem cell transplant (PBSCT). Despite the aggressive
salvage therapy, 6 patients died, and only patient 7 sur-
vived without evidence of disease. The causes of death
were tumor progression in 5 patients and metastatic
intestinal tumor complicated with intussusception and
septic shock in 1 patient (Table 2).14
The median follow-up duration for the preadoles-
cent patients was 37 months (range, 30–134 months).
The 5-year overall survival rate was 51.3% for all the
patients and 60.6% for the 11 patients without pri-
mary metastasis (Figures 1 and 2).
Comparison with the adolescent patients
The adolescent group consisted of 39 males and 19
females, with a median age of 13.8 years (range, 10.1–
17.9 years). The sex distribution indicated more com-
mon tumor occurrence in males, as in the preadolescent
group (p = 0.751; Table 3). Primary metastasis was
diagnosed in 19 patients, which was not statistically
different from the preadolescent patients (32.8% vs.
15.4%, p = 0.319). The most common tumor location
and histologic types were distal femur and osteoblastic
type, respectively, in both groups (Table 3). Thirty-
five patients received the pre-2003 protocol and 15
received the new protocol. Data on the tumor necrosis
rate induced by neoadjuvant chemotherapy were avail-
able for 42 (72.4%) patients, and 24 (57%) of these
patients were good responders. Good responders were
more common in the adolescent group (57% vs. 20%,
p=0.035). The median ALP level was 280 U/L (range,
87–2,584 U/L). The percentage of high ALP was
not different from that of the preadolescent patients
(25% vs. 30.8%, p = 0.728). The same results applied to
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Figure 1. Kaplan-Meier plot of overall survival (OS) in preadoles-
cent and adolescent patients.
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Figure 2. Kaplan-Meier plot of overall survival (OS) in patients
without primary metastasis.
the incidence of pathologic fracture (6 of 58 patients,
p = 0.35) and the rate of amputation (6 of 57 patients,
p = 0.633). The median survival time in the adolescent
group was 39 months (range, 2–168 months), and the
5-year survival rate was 56.4%. The 5-year survival
rate in the adolescent patients without primary metas-
tasis was 66.7% (Figures 1 and 2). Compared with the
51.3% for all the preadolescent patients and the 60.6%
for the preadolescent patients without primary metas-
tasis, no survival difference was found between the
groups (p = 0.735 and p = 0.925).
Discussion
This retrospective study compared the clinical charac-
teristics and outcome of osteosarcoma between 13
preadolescent and 58 adolescent patients. No differ-
ences were observed between the groups in terms of
tumor location, histologic type, primary metastasis,
pathologic fracture, and high ALP level at presenta-
tion. The only difference was a higher number of good
responders to chemotherapy in the adolescent group.
The 5-year survival rates between the groups were
similar. The survival rates of 60% and 70%, respec-
tively, in the latest large-scale study from the Rizzoli
Institute,8 comparing 133 preadolescent patients and
782 older patients (13–40 years old), were essentially
the same as our results. This report also described a
higher incidence in females and more non limb-salvage
surgeries for preadolescent patients. However, our
study found a higher incidence in male preadolescents,
as in adolescent patients and in other reports.5,6,17
Differences in race or inherent tumor properties among
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Table 3. Comparison of patient characteristics between preadolescent and adolescent patients*
Preadolescents (n = 13) Adolescents (n = 58) p
Age (yr) 4.8–9.5 10.1–17.9
Sex 0.751
Male 8 (62) 39 (67)
Female 5 (38) 19 (33)
Pathologic fracture 0.633
Yes 2 (15) 6 (10)
No 11 (85) 52 (90)
Traditional therapy before diagnosis 0.425
Yes 8 (89) 30 (73)
No 1 (11) 11 (27)
Not reported 4 17
ALP 0.728
High 4 (31) 12 (25)
Normal 9 (69) 36 (75)
Not reported 10
Tumor necrosis rate 0.035
≥ 90% 2 (20) 24 (57)
< 90% 8 (80) 18 (43)
Not reported 3 16
Histologic type 0.256
Osteoblastic 12 (92) 41 (76)
Non-osteoblastic 1 (8) 13 (24)
Not reported 4
Tumor location 0.925
Distal femur 7 (54) 26 (45)
Proximal tibia 4 (31) 19 (33)
Humerus 1 (7.5) 7 (12)
Others 1 (7.5) 6 (10)
Amputation 0.353
Yes 3 (23) 6 (11)
No 10 (77) 51 (89)
*Data presented as range or n (%). ALP = alkaline phosphatase.
preadolescent patients are possible explanations, and
further studies are necessary to arrive at a suitable con-
clusion. With regard to limb-salvage surgery, this pro-
cedure is especially challenging for preadolescent
patients because it results in unacceptable leg discrep-
ancy. Although not statistically significant, the ampu-
tation rate for our preadolescent patients was also
higher than that for the adolescent patients (23% vs.
11%). Compared with the 11% amputation rate in the
Cho et al6 study, 58% in the Rytting et al7 study, and
23% in the Bacci et al8 study, our results do not show
an especially high amputation rate in preadolescent
patients. Among the 10 preadolescent patients who
underwent limb-salvage surgery, 6 died of tumor
relapse, 1 had not reached final skeletal maturity, 
2 underwent surgery without destroying the growth
plate, and 1 underwent a lengthening operation for
leg discrepancy. Despite the high relapse rate (6 of 10)
among patients who underwent limb-salvage surgery,
local recurrence was not the main cause of relapse.
With advances in surgical techniques, including expan-
sion procedures,18 and functional and cosmetic preser-
vation for long-term survivors,19 the use of limb-salvage
surgery in preadolescent patients will increase in the
future.
Our study showed a higher number of poor
responders among the preadolescent (80%) than ado-
lescent patients (43%, p = 0.035), which has not been
observed before. The rate of 80% poor responders 
in the preadolescent group is similar to the 68%
reported by Cho et al,6 but inferior to the 37% reported
by Bacci et al.8 One possible explanation is the differ-
ent tumor biology. Another explanation is the inten-
sity of chemotherapy, which was weaker before 2003,
and most of the preadolescent patients (10 of 13) 
in this study received the pre-2003 protocol. The
chemotherapy regimens administered by Bacci et al5,8
in the Rizzoli Institute were also stronger than those
administered by Cho et al.6 Moreover, the finding
that the survival rate was not poor even with the poor
responders in the preadolescent group is interesting.
Lewis et al20 reported an improved histologic response
but not survival in osteosarcoma patients treated with
intensified chemotherapy. Eselgrim et al21 found that
higher doses of preoperative chemotherapy do not
increase the tumor necrosis rate or improve final sur-
vival. Because of the lower patient numbers and insuf-
ficient follow-up time after the new protocol, we
could not prove that intensification and stratification
of chemotherapy according to tumor necrosis rate can
improve survival, even though we observed a better
tumor necrosis rate after the use of the new protocol.
Therefore, although the tumor necrosis rate has been
documented as a prognostic factor in many stud-
ies,6,22–24 its role as a surrogate outcome measure in
protocols requires further study. Moreover, the patho-
logic assessment of the tumor necrosis rate is some-
times a problem. One reason is insufficient tissue to
evaluate the necrosis rate in patients receiving “auto-
graft” reconstruction. Another problem is that not
every pathologist follows the standard histologic clas-
sification because it is time-consuming.25 We have
attempted to use MRI and nuclear medicine studies
as auxiliary tools to estimate the tumor necrosis rate.
The conclusion regarding how the results correspond
to the pathologic necrosis rate is still pending.
We did not analyze the prognostic factors for the
preadolescent patients in our study because of the low
number of patients enrolled. Two of the preadoles-
cent patients (patients 7 and 11) with extremely high
ALP levels (twice that of normal) and without pri-
mary metastasis relapsed quickly after completion of
adjuvant chemotherapy, with both showing bony
metastasis. This observation is consistent with the fact
that a high ALP level is a poor prognostic factor.26
Whether or not extremely high ALP levels indicate a
greater possibility of bony metastasis in preadolescent
patients needs more evaluation. In addition, in our
experience, a judgment of primary metastasis is some-
times difficult, and the prognosis after relapse remains
dismal despite aggressive rescue therapy. For example,
patient 8, who showed increased uptake in the left
humerus on diagnostic bone scanning, had a negative
biopsy result initially. Despite the 100% tumor necro-
sis rate after neoadjuvant chemotherapy, relapse in the
left humerus was found 4 months after completing the
entire chemotherapy regimen. Thus, we emphasize
that primary metastasis may be vague and the clinical
course of patients with suspicious lesions should be
highly guarded. The 2 patients (patients 1 and 4) who
received autologous PBSCT died of progressive disease
and transplantation-related complications quickly,
although patient 4 was disease-free at transplantation.
As autologous PBSCT is not beneficial,27 we suggest
that it should not be used as rescue therapy for relapsed
osteosarcoma. Before the discovery of new effective
therapy for relapsed osteosarcoma,26 early diagnosis
and complete resection were considered the most
important.
We also found that Chinese traditional therapies,
including acupuncture, herbal applications, and mas-
sage, were quite commonly used in our patient popu-
lation (Table 3). These treatments can delay diagnosis
or cause micrometastasis during aggressive manipula-
tions. Although we could not collect data for all the
patients and analyze the effect on survival, the high
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prevalence of traditional therapy deserves investigation
on how it may impact osteosarcomas in the general
population.
Although this study was a retrospective analysis in
a single institute, with relatively small patient numbers,
it offers the first report on treating preadolescent
Chinese osteosarcoma patients in Taiwan. In conclu-
sion, the general appearance of osteosarcoma and sur-
vival in preadolescent patients is not different from
those seen in adolescent patients. Multicenter studies
with larger patient numbers are warranted to confirm
the characteristics of preadolescent osteosarcoma pa-
tients and the effect of tumor necrosis rate on survival.
Before the results are obtained, we suggest treating
these patients according to the same general principles
and strategies as those used for adolescent patients.
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